Host Cxcr2-dependent regulation of mammary tumor growth and metastasis

Clinical and Experimental Metastasis

Volumn 32, Issue 1, 2015, Pages 65-72

  Sharma, Bhawna ^a   Nannuru, Kalyan C ^b   Varney, Michelle L ^c   Singh, Rakesh K ^c  

^a UNIVERSITY OF WISCONSIN   (United States)

^b REGENERON PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Chemokines; CXCR2; Inflammatory response; Metastasis

Indexed keywords

CHEMOKINE RECEPTOR CXCR2; CD11B ANTIGEN; DIFFERENTIATION ANTIGEN; MONOCYTE-MACROPHAGE DIFFERENTIATION ANTIGEN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST METASTASIS; BREAST TUMOR; CANCER INCIDENCE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; IMMUNOCOMPETENT CELL; MAMMARY GLAND FAT; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); REGULATORY MECHANISM; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR VOLUME; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; EXPERIMENTAL MAMMARY NEOPLASM; GENETICS; GRANULOCYTE; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; LUNG TUMOR; MACROPHAGE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NEUTROPHIL; PATHOLOGY; SECONDARY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD11B; ANTIGENS, DIFFERENTIATION; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GRANULOCYTES; INFLAMMATION; LUNG NEOPLASMS; MACROPHAGES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; NEUTROPHILS; RECEPTORS, INTERLEUKIN-8B; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84925460892     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-014-9691-0     Document Type: Article

References (43)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 17:10
2. Jones SE (2008) Metastatic breast cancer: the treatment challenge. Clin Breast Cancer 8(3):224–233
3. Fidler IJ (2001) Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis. Surg Oncol Clin N Am 10(2):257–269
4. Langley RR, Fidler IJ (2007) Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev 28(3):297–321
5. Liotta LA, Kohn EC (2001) The microenvironment of the tumour-host interface. Nature 411(6835):375–379
6. Benoy IH, Salgado R, Van DP, Geboers K, Van ME, Scharpe S, Vermeulen PB, Dirix LY (2004) Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 10(21):7157–7162
7. Kozlowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ (2003) Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst 48:82–84
8. Sharma B, Nawandar DM, Nannuru KC, Varney ML, Singh RK (2013) Targeting CXCR2 enhances chemotherapeutic response, inhibits mammary tumor growth, angiogenesis and lung metastasis. Mol Cancer Ther 12(5):799–808
9. Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4(7):540–550
10. Lazennec G, Richmond A (2010) Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 16(3):133–144
11. Addison CL, Daniel TO, Burdick MD, Liu H, Ehlert JE, Xue YY, Buechi L, Walz A, Richmond A, Strieter RM (2000) The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR + CXC chemokine-induced angiogenic activity. J Immunol 165(9):5269–5277
12. Heidemann J, Ogawa H, Dwinell MB, Rafiee P, Maaser C, Gockel HR, Otterson MF, Ota DM, Lugering N, Domschke W, Binion DG (2003) Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J Biol Chem 278(10):8508–8515
13. Nannuru KC, Sharma B, Varney ML, Singh RK (2011) Role of chemokine receptor CXCR2 expression in mammary tumor growth, angiogenesis and metastasis. J Carcinog 10:40. doi:10.4103/1477-3163.92308 Epub@2011 Dec 31.:40-3163
14. Singh S, Wu S, Varney M, Singh AP, Singh RK (2011) CXCR1 and CXCR2 silencing modulates CXCL8-dependent endothelial cell proliferation, migration and capillary-like structure formation. Microvasc Res 82(3):318–325
15. Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH, Wang Z, Huang XW, Fan J, Zhou J (2012) Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology 56(6):2242–2254
16. Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N, Seshan VE, Norton L, Brogi E et al (2012) A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150(1):165–178
17. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, Carbone DP, Matrisian LM, Richmond A, Lin PC, Moses HL (2008) Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1 + CD11b + myeloid cells that promote metastasis. Cancer Cell 13(1):23–35
18. Liu L, Li M, Spangler LC, Spear C, Veenstra M, Darnall L, Chang C, Cotleur AC, Ransohoff RM (2013) Functional defect of peripheral neutrophils in mice with induced deletion of CXCR2. Genesis 51(8):587–595
19. Katoh H, Wang D, Daikoku T, Sun H, Dey SK, Dubois RN (2013) CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 24(5):631–644
20. Gregory AD, Houghton AM (2011) Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 71(7):2411–2416
21. Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4(1):71–78
22. Sharma B, Singh RK (2011) Emerging candidates in breast cancer stem cell maintenance, therapy resistance and relapse. J Carcinog 10:36. doi:10.4103/1477-3163.91119 Epub@2011 Dec 22.:36-3163
23. Cacalano G, Lee J, Kikly K, Ryan AM, Pitts-Meek S, Hultgren B, Wood WI, Moore MW (1994) Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. Science 265(5172):682–684
24. Aslakson CJ, Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52(6):1399–1405
25. Wilson TJ, Nannuru KC, Futakuchi M, Sadanandam A, Singh RK (2008) Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-{kappa}B ligand. Cancer Res 68(14):5803–5811
26. Varney ML, Johansson SL, Singh RK (2006) Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am J Clin Pathol 125(2):209–216
27. Abe F, Dafferner AJ, Donkor M, Westphal SN, Scholar EM, Solheim JC, Singh RK, Hoke TA, Talmadge JE (2010) Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice. Cancer Immunol Immunother 59(1):47–62
28. Brigati C, Noonan DM, Albini A, Benelli R (2002) Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis 19(3):247–258
29. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860–867
30. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436–444
31. Singh S, Varney M, Singh RK (2009) Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res 69(2):411–415
32. Aslakson CJ, Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52(6):1399–1405
33. Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA (2006) Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 42(6):768–778
34. Reutershan J, Morris MA, Burcin TL, Smith DF, Chang D, Saprito MS, Ley K (2006) Critical role of endothelial CXCR2 in LPS-induced neutrophil migration into the lung. J Clin Invest 116(3):695–702
35. Cardona AE, Sasse ME, Liu L, Cardona SM, Mizutani M, Savarin C, Hu T, Ransohoff RM (2008) Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissues. Blood 112(2):256–263
36. Jamieson T, Clarke M, Steele CW, Samuel MS, Neumann J, Jung A, Huels D, Olson MF, Das S, Nibbs RJ, Sansom OJ (2012) Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. J Clin Invest 122(9):3127–3144
37. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum D, Guan JL, Dontu G et al (2010) CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 120(2):485–497
38. Singh JK, Farnie G, Bundred NJ, Simoes BM, Shergill A, Landberg G, Howell SJ, Clarke RB (2013) Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms. Clin Cancer Res 19(3):643–656
39. Singh S, Nannuru KC, Sadanandam A, Varney ML, Singh RK (2009) CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Br J Cancer 100(10):1638–1646
40. Singh S, Sadanandam A, Nannuru KC, Varney ML, Mayer-Ezell R, Bond R, Singh RK (2009) Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clin Cancer Res 15(7):2380–2386
41. Liu X, Peng J, Sun W, Yang S, Deng G, Li F, Cheng JW, Gordon JR (2012) G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice. Tohoku J Exp Med 228(2):147–156
42. Allegretti M, Cesta MC, Garin A, Proudfoot AE (2012) Current status of chemokine receptor inhibitors in development. Immunol Lett 145(1–2):68–78
43. Nair P, Gaga M, Zervas E, Alagha K, Hargreave FE, O’Byrne PM, Stryszak P, Gann L, Sadeh J, Chanez P (2012) Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 42(7):1097–1103